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A 
nergy is a cellular state in which a lymphocyte is ahve 
but  fails  to  display certain  functional  responses  when 
optimally  stimulated  through  both  its  antigen-specific  re- 
ceptor and  any other receptors  that  are normally required 
for full  activation.  The  term  was  initially  used  by  Nossal 
and Pike (1) to describe an unresponsive state induced by the 
injection  of soluble protein  antigens  in vivo, in which  the 
antigen-specific  B  cells  were  still  found  to  be  present  in 
the animal, but these cells could not be reactivated by anti- 
gen or mitogen to make Ig. The first observation of prolif- 
erative unresponsiveness  induced  in purified  T  cells  using 
peptide antigens was made on human CD4 + clones (2).  The 
results were  initially  interpreted  as  a  direct  inactivation  of 
the  T  cells  through  recognition  of free antigen;  however, 
subsequent  blocking  studies  with  anti-Ia  antibodies  re- 
vealed  the  involvement  of MHC  class  II  molecules  (ex- 
pressed  on the  T  cells;  3).  Downregulation  of T  cell anti- 
gen receptor expression was noted after the stimulation and 
postulated to be the molecular mechanism for the blocking 
of reactivation (4). Studies with mouse CD4 § T  cell clones 
uncovered  other  ways  of inducing  an  unresponsive  state, 
which at first appeared to be similar to the nonprohferating 
state seen with human  T  cell clones  (5, 6).  Presentation  of 
peptide antigens  either on chemically fixed APCs  (5)  or in 
planar lipid membranes containing only MHC  class II mol- 
ecules (6)  was successful, as was stimulation  of highly puri- 
fied  T  cells  with  either  concanavalin  A  (7)  or  anti-CD3 
antibodies coated on a plastic surface (8). These results sug- 
gested that occupancy of the T  cell antigen receptor alone, 
in the absence of other signals, was responsible for inducing 
the  unresponsive  state.  Proof for this  came from so called 
"allogeneic  add-back"  experiments  in  which  live  APCs 
bearing  allogeneic  MHC  class  II molecules  were  used  to 
reconstitute  the  ability to stimulate a prohferative response 
and prevent the induction  of unresponsiveness,  even though 
the  allogeneic  cells themselves could  not present the  anti- 
gen to the T  cell clone (9). The allogeneic APCs were pos- 
tulated to be delivering a costimulatory signal(s) needed for 
both effects. 
When similar allogeneic add-back experiments were car- 
ried out with  purified  human  T  cell  clones  inactivated  by 
exposure  to high  concentrations  of soluble peptides,  addi- 
tion  of either  allogeneic  or  syngeneic  APC  failed  to  pre- 
vent the induction  of the unresponsiveness  (10).  This puz- 
zling  observation  was  further  compounded  when  other 
laboratories were  able to set up mixed leukocyte  responses 
(ML1Ks)  using  transfected  human  cell  lines  as  APCs  (11) 
and essentially reproduce as well as extend the earlier find- 
ings  made  in  the  murine  systems  (12).  Finally,  the  recent 
discovery of partial peptide agonist ligands has led to a new 
mouse model for anergy in which these peptides were used 
to  induce  an  unresponsive  state,  even  in  the  presence  of 
costimulation  (13).  The goal of this commentary is to sort 
through  these  various  models  of anergy  to  try  and  find 
some  common  underlying  molecular  mechanism(s)  and 
then to apply these thoughts to the new work of Groux et 
al.  (in  this  issue).  This  study adds yet another  twist  to the 
induction  process,  the  cytokine  IL-10,  which  with  TC1K 
occupancy produces an anergic state in freshly isolated hu- 
man CD4 + T  ceils that appears to be more profound than 
any of the previous in vitro models. 
Murine and Human T  Cell Anergy Induced by TCR 
Occupancy in the Absence of Costimulation 
Molecular Characterization.  Anergized  cells  generated  by 
TC1K occupancy in the absence ofcostimulation fail to pro- 
liferate  when  restimulated  with  normal  APC  and  antigen 
(4-8,  11,  12). In CD4 + Thl  clones and CD8 + CTL clones, 
this  is  caused  by a  block in  IL-2 production  (14,  15;  see 
Fig.  1).  Transcription  of the  IL-2 gene is decreased  about 
8-fold,  and IL-2 secretion is decreased N20-fold  (14). Re- 
cent  work  suggests  that  the  transcriptional  block  results 
from a failure to activate p21 ras after TCR  occupancy (16). 
This leads to a decrease in the activities of two of the MAP 
(mitogen-activated protein)  kinase pathways,  ERK  (extra- 
cellular  signal-regulated  protein  kinases)  and JNK  (c-Jun 
NH2-terminal  kinases;  17),  as well as a failure to activate a 
critical transcription  factor of the  IL-2 gene,  AP-1  (14).  In 
addition,  increased amounts of a negative regulatory factor, 
Nil-2a,  have  been  found  in  anergic  human  T  cells  (18). 
This factor has been shown  to block AP-l-induced  trans- 
activation of reporter constructs  (19). 
IL-2  is  not  the  only  cytokine  whose  production  is  di- 
minished  in anergic  T  cells  (20).  For example,  IL-3/GM- 
CSF  production  is  decreased  10-fold.  The  production  of 
other cytokines, such as IFN-% however, is hardly affected 
at all.  One of the most interesting cytokines is IL-4. In mu- 
rine Th0 cells, IL-4 production is unaffected by anergy, yet 
the  cells are prevented from prohferating  (21).  This is be- 
cause --  in addition to blocking IL-2 production --  anergy 
blocks the ability of the cells to become competent to pro- 
liferate  to an  IL-4 signal  (22).  A  similar phenomenon  oc- 
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ergy  induced  by  TCR  occu- 
pancy in the absence ofcostimu- 
lation  with  anergy induced  by 
altered peptide ligands through a 
common  underlying  molecular 
mechanism. A speculative model 
for how IL-IO may augment an- 
ergy induction is also presented. 
See the  text  for  a  detailed de- 
scription. 
curs in  the subset of Th2  cells that  can be anergized  (23). 
The  ability of IL-12 to augment  the proliferative response 
of Thl  cells is also blocked by anergy induction  (24).  Fur- 
thermore, the ability of anergic T  cells to induce B  cells to 
proliferate  is  impaired  because  the  CD4 +  T  cells  are 
blocked in  their  expression  of the  CD40  ligand  (25).  Fi- 
nally, anergic CD8 §  T  cells are blocked for IL-2 produc- 
tion, but not for TCR-dependent cytotoxicity (15). 
The common theme in all these observations is that an- 
ergy  blocks the  ability of the  cell to  produce  and/or  re- 
spond to proliferative signals. Even the block in IL-3 pro- 
duction fits into this pattern as it was recently shown that T 
cells that acquire the ability to express high affinity IL-3 re- 
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ceptors can proliferate when stimulated with a combination 
oflL-3 and IL-4 (26). In contrast, the production of the ef- 
lector cytokines IL-4 and gamma-IFN--critical for the dif- 
ferentiation  process  of Thl  and  Th2  cells--is unaffected. 
Thus, anergy appears to be a negative feedback process akin 
to a growth arrest state. 
Costimulation.  At the  time  of receptor occupancy,  co- 
stimulation blocks the induction of anergy (9, 27;  see Fig. 
1).  This  second signal can be  given up  to  2  h  after TClK 
occupancy and still have a full effect. Two hypotheses have 
been put forth to explain how this works. One is that signal 
transduction through receptors for costimulation blocks the 
production  of the  molecular inhibitors  that  cause  anergy. For example, in human  clones, B7  engagement of CD28 
blocked the increased production  of Nil-2a stimulated by 
TCR  engagement (18).  The second hypothesis is that the 
large amount of IL-2 produced in the presence of costimu- 
lation  (30-100-fold  more than without it)  either prevents 
the inhibitor from being made by signal transduction through 
the IL-2 receptor, blocks it once it has been made, or di- 
lutes it out by stimulating multiple rounds of division after 
IL-2-induced proliferation. Evidence for these latter ideas 
includes prevention ofanergy in human clones by signaling 
through antibody cross-linking of the common ~/chain of 
the  IL-2 receptor (12)  and induction  of anergy in mouse 
clones  after normal stimulation, if antibodies  to  IL-2 and 
IL-2 receptor are added (28) or if the IL-2 is washed out 12 h 
after induction  (20).  These  different  mechanisms  are  not 
mutually exclusive. 
The molecules involved in delivering costimulatory sig- 
nals  are thought  to be predominantly the  CD28  receptor 
on the T  celt and the B7 molecules (CD80 and CD86) on 
the  APC  (29,  30).  B7  engagement of CD28  leads  to  ty- 
rosine phosphorylation of the receptor's cytoplasmic tail and 
binding of phosphatidylinositol 3-kinase (31),  although this 
event has recently been shown to be nonessential for co- 
stimulation (32,  33).  This is followed eventually by activa- 
tion of  JNK, which in concert with MAP kinase activation 
via the TCR,  augments IL-2 gene transcription via phos- 
phorylation  of the Jun  protein  of the  AP-1  transcription 
factor and possibly also CD28RC  (34,  35). CD28 signaling 
also  stabilizes IL-2 mRNA posttranscriptionally by an un- 
known mechanism (36),  and this is the major mechanism 
ofcostimulation in the mouse (37). 
Reversal of  Anergy and In Vivo Models.  One of the intrigu- 
ing and most puzzling aspects of anergy is its ability to be 
reversed by stimulation of the T  cell clones with IL-2 (20). 
This is possible because the clones abnormally express low 
levels  of the  high  affinity IL-2 receptor  on  their  surface. 
The reversal is not an outgrowth of small numbers of cells 
that  failed to be anergized with  the  initial  stimulus,  since 
limiting  dilution  cloning  showed  that  all  of the  cells  re- 
verted with the same plating efficiency as normal cells after 
stimulation and growth in IL-2. The reversal was demon- 
strated at both  the  level of cytokine production  (20)  and 
transcriptional activation of the IL-2 gene (14).  In the hu- 
man model for anergy involving TCR  occupancy in  the 
absence  of costimulation,  the  anergic  state  could  not  be 
totally reversed by the addition  of IL-2 alone.  In this sys- 
tem, the cells had to be stimulated also with anti-CD2 anti- 
body (38). 
The ability to reverse anergy raises the question of the in 
vivo relevance of this state. If anergy is a form of self toler- 
ance,  why keep  these  cells  around,  where  they might be 
reactivated through  IL-2 produced by T  cells  specific for 
foreign antigens, leading to autoimmunity? This line of rea- 
soning has led some investigators to dismiss anergy as an in 
vitro  artifact  of T  cell  clones.  However,  in  vivo  studies 
with superantigens (39-41) and adoptive transfer of T  cells 
from  TCIK-transgenic  mice  (42,  43)  have  demonstrated 
that anergy can be induced in vivo. After the initial expan- 
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sion and deletion phases induced  in V[3  expressing T  cell 
subsets  by superantigens,  there  remains  a  cohort  of V[3 + 
cells that appears to be refractory to restimulation in a pro- 
liferation assay.  This population does not merely represent 
cells expressing particular V0~ chains that prevent superanti- 
gen activation in the first place,  since  on restimulation of 
the population, one can observe early tyrosine phosphory- 
lation events that are indicative of an anergic state (41, 44). 
Furthermore, restimulation with an anti-CD3 antibody also 
revealed  a  significant  decrease  in  IL-2  production  and  a 
block in proliferation  (41).  Interestingly, addition  of IL-2 
to the restimulation cultures only partially reversed this pro- 
liferative block. This observation suggests that the  anergic 
state induced in vivo also includes inhibitors of IL-2 recep- 
tor signaling, something that has never been seen in in vitro 
models with mouse clones. 
Given this strong evidence for the existence of anergy in 
vivo, one now needs to consider the involvement of this 
state in  the process of self tolerance.  Naive T  cells  of the 
standard  lineages  (i.e.,  excluding  NKI.1 +  T  cells)  make 
predominantly IL-2 in large amounts when first activated. 
If this  first  encounter  with  antigen  is  a  TC1L  occupancy 
event in the absence of costimulation, the amount of IL-2 
produced is very low and it is conceivable that an anergic 
state ensues. If such cells are specific for self antigens in the 
peripheral  tissues,  could  they serve a  useful  role?  Recent 
models  of immunity  promulgated  by Janeway  (45)  and 
Matzinger (46)  have emphasized the critical importance of 
costimulation  in  the  decision  of the  immune  system  to 
make a  response.  Particularly in  the  "danger" model,  au- 
toreactive cells  to peripheral self-antigens are viewed as  a 
possible constituent of the normal immune response to harm- 
fi.fl antigens. After serving this function and eliminating the 
danger signals,  they are postulated to rest down and even- 
tually be deleted.  In such a model, anergic cells could rep- 
resent a quiescent form of these autoreactive cells,  waiting 
for IL-2 produced by the antigen-specific response of other 
cells to be called into play. 
T Cell Anergy Induced by TCR Occupancy and IL- 10 in 
Human CD4 + PBLs 
The  induction  of unresponsiveness  in  freshly  isolated 
PBMCs when stimulated in an MLR with allogeneic cells 
in the presence ofinhibitors ofcostimulation, such as CTLA4- 
Ig, has been reported (47).  The failure to observe a second- 
ary proliferative response when these cells were stimulated 
with the same allogeneic cells  (and  to give a proliferative 
response to third party allogeneic stimulators) has been re- 
ferred to by others  as  anergy.  As pointed  out by the  au- 
thors,  however, because the frequency of responding cells 
in these cultures is low (1-5% ofT cells), it is really impos- 
sible to be certain that the cells are actually alive and non- 
functional, as opposed to having been deleted. The same is 
true for the Groux et al. report in this issue,  in which they 
use IL-10 as an inhibitor to help induce  unresponsiveness 
in  an  MLk  involving purified  human  CD4 §  T  cell  re- 
sponders. These authors, however, also studied stimulation of the freshly isolated CD4 + PBLs with cross-linked anti- 
CD3 mAbs on a plate in the presence of IL-10. The unre- 
sponsiveness induced in this  case can clearly be called an- 
ergy, since all the T  cells  are affected. The features of the 
state described bear a strong resemblance to the anergy in- 
duced in mouse and human clones with TCR  ligation in 
the absence of costimulation, although there are some im- 
portant differences. The cells appear to be blocked in their 
IL-2  and  GM-CSF  production,  as  expected  from  other 
models, but they are also blocked in their IFN-~/produc- 
tion. Signal transduction on restimulation revealed an intact 
calcium mobilization pathway and an ability to bypass the 
anergic block with phorbol esters and ionomycin.  This is 
consistent with the  recent localization  of the biochemical 
block in murine  anergy to a failure to  activate p2V  as  (16, 
17).  In contrast to  the  murine  model,  however,  the  cells 
failed to reexpress high affinity IL-2 receptors after an ap- 
propriate rest period of 10 d followed by restimulation. As 
a consequence,  they could not be stimulated with exoge- 
nous IL-2, and thus the anergic state could not be reversed. 
This is a striking difference with the clonal models, although 
as mentioned earlier, there is some evidence from mouse in 
vivo TCR-transgenic models that IL-2 receptor expression 
or signaling is also impaired (41).  These results suggest the 
possibility that there are different degrees or levels of aner- 
gic unresponsiveness, possibly relating to the degree of block 
of ras  activation.  A  partial block may prevent transactiva- 
tion  of AP-1  bound  to  phorbol  ester  response  elements, 
whereas a complete block may prevent AP-1  from partici- 
pating with NF-AT at other sites in the enhancer. Support 
for this idea can be found in the recent studies of Sundstedt 
et al.  (44),  in which repeated injections of superantigens in 
vivo created an anergic population, which upon restimula- 
tion revealed impaired NF-AT and NF-KB p65/p50 bind- 
ing, as well as impaired AP-1 binding to IL-2 enhancer re- 
sponse  elements.  Another possibility is an earlier block at 
the level of tyrosine phosphorylation of the TCR ~ chain, 
which has recently been proposed (48). 
The concept that tolerance might exist at different levels 
in vivo was first proposed by Arnold et al. (49). In this scheme, 
anergy was considered as a single stage from which the cells 
could  be  rescued.  Other  stages  included  receptor  down- 
modulation and deletion.  The new  data using IL-10 sug- 
gest that anergy itself may have different levels. This in turn 
raises  questions  about the  biological function  and fates of 
these intermediates. It has been argued that anergy is a slightly 
slower form ofT cell death by apoptosis. This is clearly not 
the  case  at  a  biochemical level.  Peripheral  deletion  of T 
cells involves engagement of Fas by Fas ligand or the TNF 
receptor by TNF  (50).  The  subsequent  FADD-mediated 
signal transduction  events  activate ICE-like proteases that 
carry out  the  programmed cell  death  (51).  This pathway 
can be blocked by protease inhibitors  (52).  Such blockers 
have no effect on the induction of anergy in mouse T  cell 
clones (Chiodetti, L., and R.H. Schwartz, unpublished ob- 
servations).  Nonetheless,  the  half-lives  of anergic  T  cells 
have not yet been measured. Because the homeostatic half- 
life of naive T  cells appears to be controlled independently 
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from that of memory T  cells (53), it would be interesting to 
know whether conventionally anergized cells had a longer 
half-hfe than those anergized either in the presence oflL-10 
or by repeated injection of superantigens.  It is conceivable 
that deeper states of anergy, representing repeated antigen 
stimulation, might lead to a more rapid elimination of the 
cells by homeostatic mechanisms other than FAS- or TNF- 
mediated killing. 
What is IL-10 doing to facilitate anergy induction?  The 
simple model is that it is blocking the delivery of costimu- 
lation (see Fig.  1). IL-10 has been reported to have a major 
effect on macrophages (54).  It can convert activated cells to 
a  resting  monocyte-like state  in  which  the  expression  of 
proinflammatory cytokines (such as IL-1, IL-12, and TNF-ot) 
and costimulatory molecules is downregulated  (55).  Other 
APC,  such as dendritic  cells,  can also  be affected (56).  In 
addition, one experiment has suggested that exposing freshly 
isolated Langerhans  cells  (the  APCs  of the  skin)  to  IL-10 
overnight can convert them from stimulators of prolifera- 
tion  to  inducers  of anergy for murine  T  cell clones  (57). 
Thus,  even in  the  cross-linked  anti-CD3  experiments  of 
Groux  et  al.,  where  contaminating  APC  in  the  purified 
CD4 + T  cell population may play a key role in providing 
costimulation, the IL-10 could be blocking their function. 
On  the  other  hand,  even in  the  IL-10-treated groups in 
this experiment, a small amount of proliferation was noted, 
suggesting  that  some  costimulation  for  IL-2  production 
may have been getting through in these cultures. Thus, the 
profound anergy brought about by IL-10 could result from 
other sites of action, particularly in the T  cell (58, 59).  IL-10 
could augment the production of Nil-2a or the inhibitor of 
p21 ra~ activation. Alternatively, it could block the downreg- 
ulation of these components by signal  transduction through 
the IL-2 receptor. In fact, a combination of all these effects 
is  possible.  Whatever  the  molecular mechanism(s),  how- 
ever, it is clear that the  observations in  this paper suggest 
that IL-10 may be useful in clinical situations in which it is 
desirable to induce profound T  cell unresponsiveness. 
Anergy Induced with Altered Peptide Ligands 
The discovery that single amino acid substitutions  in T 
cell peptide determinants could create antagonist and partial 
agonist ligands led to the discovery of some analogues that 
could induce a proliferative unresponsive state in murine T 
cell clones (13).  Stimulation with these molecules blocked 
IL-2 production by the clones after restimulation, but other 
responses remained intact, such as upregulation of the IL-2 
receptor ot chain (see Fig.  1). The bruited pattern of respon- 
siveness  observed resembled  that  of other  murine  anergy 
models, but the surprising observation was that the induc- 
tion of this state could be achieved in the presence of func- 
tional  APCs.  Even  the  addition  of anti-CD28-  or  B7- 
expressing transfectants failed to prevent the  induction  of 
unresponsiveness. Thus, costimulation, at least as delivered 
to the outside of the cell,  was not missing. Inside the cell, 
however, some interesting biochemical events were found 
to be going on  (60,  61).  Examination of phosphotyrosine blots  revealed  that  stimulation  with  partial  agonists  led  to 
three  differences  in  the  pattern  of phosphorylation  com- 
pared to stimulation  with full agonists:  (a)  Zap-70 was not 
detectably  phosphorylated;  (b)  CD3  e  chain  phosphoryla- 
tion  was  significantly  reduced;  and  (c)  the  23-kD  phos- 
phorylated  form of the  ~  chain  was  greatly reduced.  This 
diminished  signaling  pattern  is  compatible  with  the  idea 
that  the  TCR  has  low  avidity  for  the  altered  peptide 
ligand-MHC  complex, although  other models are possible 
(61).  Sloan-Lancaster and Allen interpreted  these results to 
mean  that the  partial  signaling pattern  was responsible  for 
the induction  of anergy (60). 
Further  studies,  however,  have  suggested  that  this  is 
probably not the case (60a). The unusual tyrosine phosphor- 
ylation pattern was not found when chemically fixed APC 
and full agonist peptides were used to induce anergy. Thus, 
the partial signaling is either not necessary for anergy induc- 
tion or the two unresponsive states are not equivalent.  The 
former  conclusion  is  suggested  by  the  finding  that  unre- 
sponsiveness  induced  by  altered  peptide  ligands  could  be 
prevented by the  addition  of IL-2 during the  first 24  h  of 
culture,  similar to what has been observed by Boussiotis et 
al.  (12)  for anergy induced  by TCR  occupancy in the  ab- 
sence of costimulation.  The IL-2 addition  did not alter the 
unusual  tyrosine  phosphorylation  pattern.  Thus,  this  pat- 
tern  per  se  does  not  determine  anergy  induction;  rather, 
downstream events such as the production of IL-2 are crit- 
ical.  Nonetheless,  if the  anergic  state is comparable to that 
in other models, events such as the induction  of an inhibi- 
tor of ras activation must be induced  under these signaling 
conditions  (see Fig.  1). Whether  Nil-2a  would  also be in- 
duced is unclear.  The defect in the partial agonist stimula- 
tion would then be the inabihty to provide enough signal- 
ing  through  the  calcium/calcineurin  and/or  MAP  kinase 
pathways to synergize with  an intact CD28  signaling path- 
way  to  produce  sufficient  IL-2  to  block  the  induction  or 
function  of  the  inhibitor  of  p21 ~  activation.  Thus,  as 
shown in Fig.  1, the anergic state achieved with partial ag- 
onists in the presence  of costimulation  could be similar to 
the  anergic  state  induced  by  TC1L  occupancy  in  the  ab- 
sence  of costimulation,  but  different  from  normal  activa- 
tion, where all the inhibitors  are blocked. 
Human T  Cell Clones Stimulated in the Presence of High 
Concentrations of Soluble Peptides 
This model does not exist in the mouse because activated 
mouse T  cells do not express MHC  class II molecules, which 
are required  for the  induction  process  (3).  Like the partial 
agonist model,  the presence of professional APCs does not 
inhibit  the  induction  of unresponsiveness  (10,  62).  In fact, 
the presence of APCs leads to a large proliferative response. 
Thus,  IL-2 can be produced by the cells, and still the unre- 
sponsive state is induced.  Single cell studies in agarose ma- 
trices suggest that antigen presentation is required by one T 
cell to another, but antigen-pulsing experiments do not work, 
indicating that some interaction of the soluble antigen with 
the responding T  cell is required for the effect (62). The state 
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of unresponsiveness is deep, i.e., the cells make few detect- 
able  lymphokines  on  restimulation,  similar  to  the  IL-10 
model  (10).  Induction  of this  state  is  accompanied  by  a 
down  modulation  of both  CD28  and  the  TCR  complex 
(4, 63). Molecular studies have suggested an impaired intra- 
cellular calcium response  (62)  and a diminished  binding of 
the  NF-AT  transcription  factor to the  distal  response  ele- 
ment  in  the  IL-2  enhancer,  with  no  significant  effect on 
AP-1  (64). The block in IL-2 production  can be overcome 
by a calcium ionophore. 
Although  not  all  the  desired  biochemical  studies  have 
been  done  in  this  system  (e.g.,  measuring  the  activation 
ability ofp21r~s), I do not perceive a clear way to unify this 
model  with  all  the  others  I  have  discussed.  It  appears  to 
represent a block in the calcium/calcineurin  pathway rather 
than  the  ras/MAP  kinase pathway.  It is a  reproducible  ef- 
fect  having  been  demonstrated  in  several  laboratories.  It 
can be induced  in  activated as well  as  resting T  cells and, 
therefore,  could  be  of great  importance  in  manipulating 
clinical states during acute  onset of diseases (63). The clos- 
est mouse model that I have seen to this  state is the  unre- 
sponsiveness  of T  cell  clones  studied  by  Otten  and  Fitch 
(65).  This also appears to be a block in the calcium-signal- 
ing pathway;  however,  it  is induced  by signaling  through 
the  IL-2 receptor and appears to be a mechanism to block 
signaling through  the TCR. when the  cell is in cycle. This 
mechanism  possibly  exists  as  a  buffer  on  the  propriocidal 
effect  (66).  Unlike  the  human  clonal  anergy,  however,  it 
can be overcome by stimulating  with  high  concentrations 
of antigen,  and the state spontaneously decays when the T 
cells are rested in culture for 5-7 d. Another possible unre- 
sponsive state that could be a model for this human  clonal 
anergy is the veto effect (67). I have discussed this idea be- 
fore (68), and recent studies with mouse CD8 § T  cell clones 
provide  support  for a  model in which  reciprocal recogni- 
tion  of one  T  cell by the  antigen-specific  receptor  of the 
other inactivates both cells  (69).  Nothing  is known,  how- 
ever, about the biochemistry of the unresponsive state that 
is induced,  so it is difficult  to rigorously  compare the  two 
effects. Further studies are required  to clarify this situation. 
At the present  time,  I  would  suggest that this  form of an- 
ergy be kept  distinct  from  other  models  in  the  literature, 
perhaps by referring to it as calcium-blocked anergy in con- 
trast to ras-blocked anergy. 
Conclusions 
Since  the  initial  discovery  of an  anergic  state  in  T  cell 
clones,  a variety of models  of unresponsiveness  have been 
developed  that  have  been  given  the  same  descriptor.  At 
one point in time, almost every tolerance model pubhshed 
was attributed  to anergy,  without  any clear attempt  to as- 
certain whether the minimal requirements had been met of 
a live cell that was functionally unresponsive in at least some 
assay. In more recent times, with the shif~ in fashion to apop- 
tosis as the  universal mechanism for tolerance,  the number 
of models of unresponsiveness  attributed  to anergy has re- 
turned  to  realistic  proportions.  Although  some  peripheral deletion  addicts  would  like  to  herd  anergy  models  into 
their corral as a slow form of cell death, the recent charac- 
terizations  of the  underlying biochemical mechanisms  of 
the two processes have  clearly delineated the pathways. In 
this overview of the various currently accepted models for 
anergy,  I  have  attempted  to  find  a  unifying  molecular 
mechanism to comment on the new paper by Groux et al. 
in this issue, which introduces IL-10 as a tool for facilitat- 
ing the induction of the state. I think that all but one of the 
models can be understood in the same way. The state is in- 
duced by a TCR  occupancy event that stimulates the pro- 
duction of several inhibitors, one that blocks p21 ras activa- 
tion and another (Nil-2a) that blocks cytokine transcription. 
These  inhibitors  prevent  transcription  of IL-2  and  other 
cytokines, and they block proliferative pathways when the 
cell is reactivated. The induction of these inhibitors is nor- 
mally  antagonized  by  costimulation  involving  signaling 
through receptors such as CD28,  and proliferation induced 
by signaling through the IL-2 receptor. The anergic state is 
stable and seems to exist at different levels depending possi- 
bly on  the  concentrations of the molecular inhibitors that 
are induced. Cells in this state have been found in vivo af- 
ter injecting mice with superantigens. In contrast to this "ras- 
blocked"  anergy,  high  concentration  of peptides  adminis- 
tered to  human  T  cell  clones  produces  inhibition  of the 
calcium/calcineurin  signaling pathway  ("calcium-blocked" 
anergy)  accompanied by a  downmodulation  of the  TCR 
and CD28.  The critical biological question remaining to be 
answered is, what role, if any, do these anergic cells play in 
an immune response and/or in tolerance induction? 
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